Literature DB >> 30258533

Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.

Ted W Johnson1, Ben Bolanos1, Alexei Brooun1, Rebecca A Gallego1, Dan Gehlhaar1, Mehran Jalaie1, Michele McTigue1, Sergei Timofeevski1.   

Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that can become oncogenic by activating mutations or overexpression. Full kinetic characterization of both phosphorylated and nonphosphorylated wildtype and mutant ALK kinase domain was done. Our structure-based drug design programs directed at ALK allowed us to interrogate whether X-ray crystallography data could be used to support the hypothesis that activation of ALK by mutation occurs due to increased protein dynamics. Crystallographic B-factors were converted to normalized B-factors, which allowed analysis of wildtype ALK, ALK-C1156Y, and ALK-L1196M. This data suggests that mobility of the P-loop, αC-helix, and activation loop (A-loop) may be important in catalytic activity increases, with or without phosphorylation. Both molecular dynamics simulations and hydrogen-deuterium exchange experimental data corroborated the normalized B-factors data.

Entities:  

Year:  2018        PMID: 30258533      PMCID: PMC6142052          DOI: 10.1021/acsmedchemlett.8b00348

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  40 in total

1.  Dynamics of the trimeric AcrB transporter protein inferred from a B-factor analysis of the crystal structure.

Authors:  W C Lu; C Z Wang; E W Yu; K M Ho
Journal:  Proteins       Date:  2006-01-01

2.  Conformational Rigidity and Protein Dynamics at Distinct Timescales Regulate PTP1B Activity and Allostery.

Authors:  Meng S Choy; Yang Li; Luciana E S F Machado; Micha B A Kunze; Christopher R Connors; Xingyu Wei; Kresten Lindorff-Larsen; Rebecca Page; Wolfgang Peti
Journal:  Mol Cell       Date:  2017-02-16       Impact factor: 17.970

Review 3.  Kinases and pseudokinases: lessons from RAF.

Authors:  Andrey S Shaw; Alexandr P Kornev; Jiancheng Hu; Lalima G Ahuja; Susan S Taylor
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

Review 4.  Active and inactive protein kinases: structural basis for regulation.

Authors:  L N Johnson; M E Noble; D J Owen
Journal:  Cell       Date:  1996-04-19       Impact factor: 41.582

5.  9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.

Authors:  Kazutomo Kinoshita; Takamitsu Kobayashi; Kohsuke Asoh; Noriyuki Furuichi; Toshiya Ito; Hatsuo Kawada; Sousuke Hara; Jun Ohwada; Kazuo Hattori; Takuho Miyagi; Woo-Sang Hong; Min-Jeong Park; Kenji Takanashi; Toshiyuki Tsukaguchi; Hiroshi Sakamoto; Takuo Tsukuda; Nobuhiro Oikawa
Journal:  J Med Chem       Date:  2011-08-25       Impact factor: 7.446

6.  A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.

Authors:  Hui-Yong Sun; Feng-Qin Ji
Journal:  Biochem Biophys Res Commun       Date:  2012-05-30       Impact factor: 3.575

7.  Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

Authors:  Christian C Lee; Yong Jia; Nanxin Li; Xiuying Sun; Kenneth Ng; Eileen Ambing; Mu-Yun Gao; Su Hua; Connie Chen; Sungjoon Kim; Pierre-Yves Michellys; Scott A Lesley; Jennifer L Harris; Glen Spraggon
Journal:  Biochem J       Date:  2010-09-15       Impact factor: 3.857

8.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

Authors:  Ted W Johnson; Paul F Richardson; Simon Bailey; Alexei Brooun; Benjamin J Burke; Michael R Collins; J Jean Cui; Judith G Deal; Ya-Li Deng; Dac Dinh; Lars D Engstrom; Mingying He; Jacqui Hoffman; Robert L Hoffman; Qinhua Huang; Robert S Kania; John C Kath; Hieu Lam; Justine L Lam; Phuong T Le; Laura Lingardo; Wei Liu; Michele McTigue; Cynthia L Palmer; Neal W Sach; Tod Smeal; Graham L Smith; Albert E Stewart; Sergei Timofeevski; Huichun Zhu; Jinjiang Zhu; Helen Y Zou; Martin P Edwards
Journal:  J Med Chem       Date:  2014-06-03       Impact factor: 7.446

9.  Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Authors:  Ryohei Katayama; Luc Friboulet; Sumie Koike; Elizabeth L Lockerman; Tahsin M Khan; Justin F Gainor; A John Iafrate; Kengo Takeuchi; Makoto Taiji; Yasushi Okuno; Naoya Fujita; Jeffrey A Engelman; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2014-09-16       Impact factor: 12.531

10.  Evidence for dynamics in proteins as a mechanism for ligand dissociation.

Authors:  Mary J Carroll; Randall V Mauldin; Anna V Gromova; Scott F Singleton; Edward J Collins; Andrew L Lee
Journal:  Nat Chem Biol       Date:  2012-01-15       Impact factor: 15.040

View more
  2 in total

1.  Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib.

Authors:  Ted W Johnson; Rebecca A Gallego; Alexei Brooun; Dan Gehlhaar; Michele McTigue
Journal:  ACS Med Chem Lett       Date:  2018-06-18       Impact factor: 4.345

2.  Substrate-binding destabilizes the hydrophobic cluster to relieve the autoinhibition of bacterial ubiquitin ligase IpaH9.8.

Authors:  Yuxin Ye; Yuxian Xiong; Hao Huang
Journal:  Commun Biol       Date:  2020-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.